| 4.0653 -0.145 (-3.44%) | 09-21 15:41 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.95 | 1-year : | 11.66 |
| Resists | First : | 7.66 | Second : | 9.98 |
| Pivot price | 4.42 |
|||
| Supports | First : | 3.91 | Second : | 3.25 |
| MAs | MA(5) : | 4.17 |
MA(20) : | 4.81 |
| MA(100) : | 6.6 |
MA(250) : | 10.96 |
|
| MACD | MACD : | -0.6  |
Signal : | -0.6 |
| %K %D | K(14,3) : | 14.8 |
D(3) : | 11.8 |
| RSI | RSI(14): 40.2 |
|||
| 52-week | High : | 32.54 | Low : | 2.44 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AMIX ] has closed above bottom band by 8.4%. Bollinger Bands are 82.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.4 - 4.43 | 4.43 - 4.45 |
| Low: | 4.11 - 4.14 | 4.14 - 4.17 |
| Close: | 4.16 - 4.21 | 4.21 - 4.25 |
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
Thu, 17 Sep 2026
Autonomix Medical (NASDAQ: AMIX) Welcomes Sandra Kalter to Board of Directors - Kalkine Media
Wed, 16 Sep 2026
Autonomix Medical Adds Former Medtronic Regulatory Executive Sandra Kalter to Board - citybiz
Wed, 16 Sep 2026
Sandra Kalter appointed to Autonomix Medical board as independent director - TradingView
Wed, 16 Sep 2026
Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors - finance.yahoo.com
Wed, 16 Sep 2026
Autonomix Medical, Inc. SEC Filing (Sep 16, 2026) - Stock Titan
Tue, 01 Sep 2026
Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026 - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 5.8 (%) |
| Shares Short | 109 (K) |
| Shares Short P.Month | 62 (K) |
| EPS | -31.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.82 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -157.9 % |
| Return on Equity (ttm) | -316 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -16.86 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.14 |
| PEG Ratio | 0 |
| Price to Book value | 0.69 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|